Pharmacy Daily | TGA tests PPI CV risk

The TGA has conducted an evaluation of cardiovascular disease risk associated with the use of proton pump inhibitors (PPIs) after two independent studies found a positive correlation. The TGA said neither study was designed to address the possibility that PPI use was itself a marker of increased cardiovascular risk, as information on “significant baseline risk factors was not collected,” and concluded that the studies did not demonstrate an increased cardiovascular risk for PPIs that was independent of the patient population in which they were being used. The update was included in the latest Medicines Safety Update from the TGA which also looked at IUDs and uterine perforation, potential interactions between allopurinol and 6-mercaptopurine/ azathioprine, plus peginterferon alfa-2a and facial palsy. The TGA also yesterday advised that the product information for varenicline (Champix) has recently been updated with new safety information in relation to the risks of psychiatric symptoms and potential interaction with alcohol - for details see tga.gov.au.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 03 Dec 15
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Dec 15